Story perspectives

Roche Acquires 89bio for $3.5 Billion to Boost Liver Treatments

9/18/2025

Summary

Story summary

Roche will acquire U.S.-Israeli biotech firm 89bio for up to $3.5 billion, focusing on liver disease treatments.
The deal offers $14.50 per share in cash and a contingent value right of up to $6 per share based on future milestones.
89bio's lead drug, pegozafermin, targets metabolic dysfunction-associated steatohepatitis (MASH), linked to obesity.
The acquisition enhances Roche's portfolio in metabolic and cardiovascular diseases, reflecting a strategic shift towards metabolic disorders.
Analysts see this move as a response to increasing competition in the weight-loss drug market.

History

Historical Context

In 2019, the FDA approved the first drug for nonalcoholic steatohepatitis (NASH), a condition impacting over 16 million Americans. Roche's $3.5 billion acquisition of 89bio reflects the pharmaceutical industry's increasing focus on metabolic diseases amid rising obesity rates. This strategic shift underscores Roche's commitment to addressing the growing health crisis associated with metabolic disorders and the competitive landscape of weight-loss treatments.

1 of 2

Story summary

Roche will acquire U.S.-Israeli biotech firm 89bio for up to $3.5 billion, focusing on liver disease treatments.
The deal offers $14.50 per share in cash and a contingent value right of up to $6 per share based on future milestones.
89bio's lead drug, pegozafermin, targets metabolic dysfunction-associated steatohepatitis (MASH), linked to obesity.
The acquisition enhances Roche's portfolio in metabolic and cardiovascular diseases, reflecting a strategic shift towards metabolic disorders.
Analysts see this move as a response to increasing competition in the weight-loss drug market.

1 / 2